Biological Activity |
Gly-beta-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders[1]. IC50 & Target: FXR[1]. In Vitro: Gly-beta-MCA, a bile acid, is a potent, sable and intestine-selective and farnesoid X receptor (FXR) inhibitor[1]. Gly-beta-MCA (Gly-MCA, ) is resistant to hydrolysis by BSH[1]. In Vivo: Gly-beta-MCA (Gly-MCA, p.o. 10 and 50 mg/kg) prevents and treats diet-induced and genetic obesity, along with insulin resistance and hepatic steatosis without systemic, hepatic or intestinal toxicities in mice[1]. Gly-MCA does not increase faecal LCN-2 levels, indicating that Gly-MCA does not induce intestinal inflammation[1]. |